Eurofarma participates in CPhI Worldwide and seeks partners to market and license medications
The event is one of the most important in the pharmaceutical industry and the company wants to expand relationships with companies to further extend its global presence
São Paulo, October 28, 2022 – Between November 1 and 3, Eurofarma, a Brazilian pharmaceutical company present in more than 20 countries in Latin America and Africa, participates as an exhibitor in CPhI Worldwide, the most important event in the pharmaceutical industry, which this year will take place in Frankfurt, Germany. The company will have a booth in the "Brazilian Pavilion," a space organized by Abiquifi (Brazilian Association of the Pharmaceutical Industry and Pharmaceutical Inputs).
Eurofarma has participated for more than 15 years in the event, which this year is expected to welcome more than 2,500 exhibitors from more than 170 countries, with approximately 45,000 visitors. "CPhI has become a reference in the pharmaceutical market and we continue to participate in the meeting to strengthen relationships with several global companies. It is an excellent opportunity for industry professionals to meet and learn about eveyrhing new that has been brought to market. Our focus is to establish great partnerships," says Walker Lahmann, Executive Director of New Markets at Eurofarma.
In 2022 Eurofarma celebrated 50 years of history – marked, among other pillars, by internationalization. More than 10 years ago, the company began its expansion process outside Brazil, and today it is present in 100% of Latin America and some African countries, in addition to working on the export front. This business unit started operating in 2002 and expanded in the last year the portfolio of products exported to countries in which it already operates, such as Paraguay, Uganda, Angola, and Mozambique, with more than 27 new products.
Along with export, right now the company is also focusing on outsourcing, aiming to form partnerships to produce, even in a custom-made way, medications for other companies. The company has 10 production plants in Latin America, which offer the possibility of manufacturing various classes of pharmaceutical products and forms, such as solids, semi-solids, injectables, oncologicals, among many others.
For more information about CPhI 2022, please visit: cphi.com/europe.
About Eurofarma Group
The Eurofarma Group has been operating in the healthcare industry for 50 years, producing and marketing innovative products and services to improve people’s quality of life. With diversified operations, it operates in all major segments, such as Medical Prescription, Prescription-Free, Generic, Hospital and Oncology, in addition to exporting and outsourcing medications. In Brazil alone, it offers more than 430 products, serves all medical specialties, and covers upwards of 200 therapeutic classes, accounting for 80% of the total market.
The Eurofarma Group is present in more than 20 countries, with 10 manufacturing plants in Latin America. Reported net sales totaled BRL 7 billion in 2021 and the Group employs over 8,800 people.
Eurofarma on social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma | Youtube: @eurofarmalab
Press Information
G&A – Public Relations
Carolina Carone - +55 11 98578-1604 - carolina.carone@gaspar.com.br
Guilherme Gaspar - +55 11 98285-6000 - guilherme@gaspar.com.br